Abstract:The realization that the human microbiome (HM) is a significant contributor to nutrition, health and disease is a relatively recent one, however, mechanistic studies linking alterations in microbiota to the etiopathology of disease are relatively few. The HM appears to modulate the regulation of multiple neurochemical pathways through a complex series of highly interactive and symbiotic host-microbiome signaling-systems that mechanistically link the gastrointestinal (GI) tract to the central nervous system (CNS), the enteric nervous system and the neuroendocrine and immune systems.Varying combinations of GI tract bacterial species amongst human populations (i.e. different ' enterotypes') contribute to the idea of ' human-biochemical-individuality' and differential susceptibility to disease. In these preliminary studies we evaluated the effects of the anti-amyloid, anti-oxidant, anti-inflammatory flavonoid quercetin on growth inhibition of the HM-representative Bacteroides galacturonicus (ATCC 43244). Increases in B. galacturonicus in the GI tract have been associated with high fat-cholesterol (HF-C) diets, insulin resistance, diabetes and systemic inflammation. These studies are the first directly linking a major component of the HM to pathological mechanisms associated with Alzheimer's disease (AD), a progressive inflammatory neurodegeneration of the human CNS. Aβ-peptide assay; B.galacturonicus culture; cell-viability assay; minimal inhibitory-concentration (MIC) assay; human neuronal-glial (HNG) primary co-culture; reactive-oxygen-species (ROS) assay; 5-6-carboxy-2',7'-dichloro-fluorescein diacetate (dicarboxy-DCFDA); quercetin assay; RT-PCR; Western immunoassay. Species of the gram negative, obligate anaerobic Bacteroides constitute up to 35% of all HM bacteria, indicating that this genus is a significant component of the HM system. Quercetin was found to strongly inhibit B. galacturonicus proliferation (MIC∼10 μg/ml); using dicarboxy-DCFDA assay quercetin was found to decrease free radical (ROS) production and elicit neuroprotection in stressed HNG cultures. Besides quercetin's anti-oxidant activities this flavonoid may exert beneficial microbiome effects through its inhibition of B. galacturonicus and the homeostatic stabilization the HM. Neuroprotective functions of quercetin and related-flavonoid polyphenols may be to augment or modify the biochemistry or proliferation of HM-resident bacteria such as B. galacturonicus. Bacteroides infections are associated with the release of nucleic acids, lipopolysaccharide (LPS), metalloprotease and other bacterial endotoxins that contribute to amyloidogenesis and inflammatory degeneration. Several additional potential mechanisms by which Bacteroides- mediated alterations in the HM may contribute to AD include molecular-mimicry of host proteins, generation of toxic-metabolites and endotoxins, modification of absorption across the GI tract, and contribution to systemic and/or chronic CNS inflammation in the host, or by complex combinations of these pathogenic processes. In addition to quercetin's anti-amyloid and anti-inflammatory activities this phytochemical may also exert health benefits through inhibition of B. galacturonicus- mediated proliferation of pathological signaling in both the GI tract and the CNS.

Epigallocatechin-3-Gallate and Genistein for Decreasing Gut Dysbiosis, Inhibiting Inflammasomes, and Aiding Autophagy in Alzheimer's Disease

Gut Microbiota Mediates Neuroinflammation in Alzheimer’s Disease: Unraveling Key Factors and Mechanistic Insights

Epigallocatechin Gallate Modulates Microglia Phenotype to Suppress Pro-inflammatory Signalling Cues and Inhibit Phagocytosis

Association Between the Gut Microbiota and Alzheimer's Disease: An Update on Signaling Pathways and Translational Therapeutics

Ginkgo biloba Extract Drives Gut Flora and Microbial Metabolism Variation in a Mouse Model of Alzheimer's Disease

Multifaceted neuroprotective effects of (-)-epigallocatechin-3-gallate (EGCG) in Alzheimer’s disease: an overview of pre-clinical studies focused on β-amyloid peptide

Ginkgo Biloba Extract Drives Gut Flora and Microbial Metabolism Variation in a Mouse Model of Alzheimer’s Disease

The Potential Role of Polyphenols in Oxidative Stress and Inflammation Induced by Gut Microbiota in Alzheimer’s Disease

The Gut Microbiota Modulates Neuroinflammation in Alzheimer's Disease: Elucidating Crucial Factors and Mechanistic Underpinnings

Gut Microbiota and Dysbiosis in Alzheimer’s Disease: Implications for Pathogenesis and Treatment

Gut-brain axis through the lens of gut microbiota and their relationships with Alzheimer's disease pathology: Review and recommendations

Emerging role of gut microbiota dysbiosis in neuroinflammation and neurodegeneration

P4-236: alzheimer's disease and the microbiome

Alzheimer's Disease and Green Tea: Epigallocatechin-3-Gallate as a Modulator of Inflammation and Oxidative Stress

Gut Microbiota Mediates Neuroinflammation in Alzheimer's Disease: Unraveling Key Factors and Mechanistic Insights

Epigallocatechin-3-Gallate Inhibits Oxidative Stress Through the Keap1/Nrf2 Signaling Pathway to Improve Alzheimer Disease

A Review of the Brain-Gut-Microbiome Axis and the Potential Role of Microbiota in Alzheimer's Disease

Brain-Gut-Microbiota Axis in Alzheimer’s Disease

Gut Microbiota Composition and Epigenetic Molecular Changes Connected to the Pathogenesis of Alzheimer's Disease

The efficacy of Epigallocatechin-3-gallate (green tea) in the treatment of Alzheimer’s disease: an overview of pre-clinical studies and translational perspectives in clinical practice

Taming neuroinflammation in Alzheimer's disease: The protective role of phytochemicals through the gut-brain axis